Pfizer (NYSE:PFE) is overhauling its cardiometabolic ... the oral GLP-1 agonist danuglipron was the right decision for the company after a patient in a dose-optimization study developed liver ...

CEO Albert Bourla said discontinuing the oral GLP-1 agonist danuglipron was the right decision for the company after a patient in a dose-optimization study developed liver injury. He added that Pfizer ...

Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

Pfizer has received a “Moderate Buy” consensus from fifteen analysts, signaling cautious optimism rather than fanfare. One ...

If the tariff-loving leader goes ahead with his plans, it will hit AstraZeneca – the most valuable company on the UK stock ... used to make them. In the eyes of many, tariffs on essential ...

Last week, Pfizer announced that it would no longer develop danuglipron, a daily GLP-1 weight-loss drug which investors were excited about as a potential blockbuster for the company. This wasn't ...

Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Company will instead invest in earlier-stage treatments for obesity Pfizer Inc. will stop developing an obesity pill that has been closely watched by investors. AFP Pfizer Inc. will stop ...

Pfizer is officially bidding adieu to its sprawling research site in San Diego as it readjusts its local footprint and moves into a new site. The company sold its five-building campus, located on ...

Also in Q1, Pfizer took in some $6.3 billion from selling its remaining shares in Haleon, the OTC company formed out of the former consumer health businesses of both Pfizer and GSK.